OncoMatch/Clinical Trials/NCT07301801
Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors
Is NCT07301801 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Injection of 68Ga-FL-031 and Injection of 18F-FDG for malignant tumors.
Treatment: Injection of 68Ga-FL-031 · Injection of 18F-FDG — The project's objective is to recruit patients with clinically confirmed or suspected small cell lung cancer, breast cancer, nasopharyngeal carcinoma and other tumours for 68Ga-FL-031 PET imaging and 18F-FDG PET imaging. The histopathology of biopsy or surgical specimens was taken as the final diagnostic criteria, and the presence or absence of tumour lesions was confirmed by the aforementioned imaging. The location and nature of the lesion, and the presence or absence of metastasis, were then judged. The objective was to analyse and clarify the diagnostic efficacy of 68Ga-FL-031 PET imaging for the aforementioned malignant tumours. The objective of this study is to analyse the correlation between the 68Ga-FL-031 PET imaging tumour tissue uptake value and the tumour tissue immunohistochemical staining SSTR2 target expression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Excluded: SSTR2 intolerance to SSTR2 targeted substances
patients must be excluded on the basis of their known intolerance to SSTR2 targeted substances
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify